

*Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the publication of this announcement, this information is now considered to be in the public domain.*

## Feedback plc

### Feedback secures CDC pathway pilot with Oldham CDC, part of the Northern Care Alliance

- Third CDC pilot site announced since December 2023
- Focused on further demonstrating the impact of a pathway approach on CDC utilisation and wider patient wait times

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical infrastructure specialist, announces that it has secured funding of £50,000 for a further Community Diagnostic Centre ("CDC") pathway pilot with the Oldham CDC, run by the Northern Care Alliance. This follows the two pilot sites, Amersham CDC in Buckinghamshire and a pan regional pilot across Buckinghamshire, Oxfordshire and Berkshire ICS ("BOB ICS"), announced on 19 December 2023. The Company has contracted directly with Oldham CDC using an additional award of funding locally disbursed for this purpose under NHS England's ("NHSE"), CDC Programme.

The contract entered into this week reflects advisory services Feedback has and continues to provide to Oldham CDC for the four-month period ended 31 March 2024 in relation to pathways development and deployment of the Company's market leading symptom-based pathway tool, Bleepa. On completion of the initial milestones, the Company will support Oldham CDC to apply for more funding from the 2024-25 NHS budget to extend the pilot with a view to installing Bleepa and establishing a live breathlessness pathway for patients. This will be used to complement findings from the ongoing pilots in Amersham CDC and BOB ICS, and follows the success of the ongoing pilot at Queen Victoria Hospital ("QVH") / Sussex Integrated Care System ("Sussex ICS") for the breathlessness pathway.

The Company continues to focus on providing reference points for commercial contracts and building the case for subsequent funding of a wider pathway approach to CDC delivery.

**Dr Tom Oakley, CEO of Feedback plc said:** *"We are gaining momentum in the CDC space following the funding support released by NHSE. Each additional site builds the evidence base for wider rollout and helps convince the wider NHS of the unquestionable benefits of the symptom-based, straight-to-diagnostic pathway approach.*

*"A national conversation is growing around how CDCs can be used to drive down waitlists and demonstrates how the NHS can achieve a return on their capital investments to date in building CDCs. This is about leveraging the diagnostic outputs of the CDC to drive down waitlists by integrating them into patient pathways.*

*"We are focused on further demonstrating the impact of a pathway approach on CDC utilisation and wider patient wait times - by providing multiple service lines and mutual aid delivery models for sharing workforce capacity at a regional basis through the Bleepa platform. We continue to have a number of discussions at the local, regional and national levels with NHS bodies and anticipate further updates in the coming months.*

*"Furthermore, we are encouraged by the increased NHS spending announced in the Spring Budget, highlighting the importance of investing in digital capabilities for the UK healthcare system. It is essential that the UK has a modern system that is able to provide timely care for patients - and we believe that Bleepa could have an integral role to play."*

–Ends–

#### Enquiries:

**Feedback plc**  
Tom Oakley, CEO  
Anesh Patel, CFO

+44 (0) 20 3997 7634  
[IR@fbk.com](mailto:IR@fbk.com)

**Panmure Gordon (UK) Limited (NOMAD and Broker)**

+44 (0)20 7896 2500

Emma Earl/Freddy Crossley (Corporate Finance)  
Rupert Dearden (Corporate Broking)

+44 (0)20 7886 2500

**Walbrook PR Ltd;**  
Nick Rome/Joe Walker

Tel: 020 7933 8780 or [feedbackplc@walbrookpr.com](mailto:feedbackplc@walbrookpr.com)  
07748 325 236 or 07407 020 470

### **About Feedback**

Feedback plc helps clinical teams to make better decisions faster for patients. We design products that enhance clinician access to patient data and to their colleagues. Our unique approach centres around individual patient episodes, into which we pull relevant clinical data from hospital systems and around which we build remote clinical teams for collaboration. As a result, we produce a digital infrastructure that makes patient data available to clinicians in multiple settings, in a format that enables them to meaningfully interact with it, providing flexibility to clinicians and free movement of patients between provider settings - clinicians can practice from anywhere and patients can attend any care provider for treatment.

Our products Bleepa and CareLocker work together to deliver unparalleled value to our customers. Bleepa is our application layer and sits on top of CareLocker as our data layer. Bleepa is a clinician facing platform that displays clinical results from a patient's CareLocker at a certified and regulated quality, that is suitable for clinical use and enables dialogue on a patient-by-patient basis with colleagues through a secure, auditable chat interface that links back to the patient medical record. The CareLocker data storage model is built around the patient. Our vision is one where relevant clinical data is always available to the patient as well as to any care setting that they may attend - a federated data architecture with the patient as the tenant.

The Company has a number of growth opportunities domestically and internationally across a range of markets including the NHS, the veterinary market and private healthcare providers and its highly scalable Software as a Service ("SaaS")-based model is expected to provide increasing levels of revenue visibility as the Company grows its customer base.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCKZGZFGDGDZM